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It is relatively difficult to diagnose bacterial sepsis in nephrolithiasis patients.The aim of the study is to evaluate the diagnostic ability
of presepsin in the differential diagnosis including SIRS, infection, or sepsis and to compare its diagnostic value with other markers,
mainly as CRP, procalcitonin (PCT), and white blood cell (WBC) in patients of nephrolithiasis presenting with SIRS. 39 patients of
nephrolithiasis who were diagnosed as SIRS were prospectively investigated. Plasma presepsin was detected by Pathfast presepsin
assay system; CRP and PCT were measured as well. Additionally, 25 nephrolithiasis patients without SIRS were included. At all
timing samples, patients were classified as SIRS or non-SIRS group. Median plasma presepsin levels were significantly increased in
the SIRS group compared with non-SIRS group (452 pg/mL versus 178 ng/mL, 𝑃 < 0.001), and presepsin was markedly elevated
even in the early stage of SIRS (584 pg/mL 6 h, 660 pg/mL 24 h versus 452 pg/mL, 𝑃 < 0.001). According to the receiver-operating
characteristic (ROC) analysis, presepsin demonstrated a high diagnostic value compared with either PCT or CRP. In the early stage
of SIRS, presepsin remained a highly sensitive (74.7%) and specific (88.4%) diagnostic marker compared with either PCT, CRP, or
WBC. Moreover, the areas under the curve (AUCs) of presepsin (84.6%) were also superior to those seen in either PCT (79.6%) or
CRP (71.8%). Thus plasma presepsin levels have comparable performance in SIRS for patients with nephrolithiasis.
1. Introduction
Nephrolithiasis can be caused by multiple factors and may
exist in any part of the urinary system with renal calculus
being the most common [1, 2]. Percutaneous nephrolitho-
tomy (PNL) is themain treatmentmodalities for nephrolithi-
asis in the present. PNL can have great influences on the
body because of trauma, pain, infection, inflammation, and
so forth, so stress response may lead to the elevation of
inflammatory factors, such as the acute phase C-reactive
protein (CRP), cytokines interleukin-1 (IL-1), interleukin-6
(IL-6), interleukin-2 (IL-2), interleukin-10 (IL-10), and TNF-
𝛼 [3, 4]. Systemic inflammatory response syndrome (SIRS)
accompanied by an infection is called sepsis, in the field of
urology; it is also called urosepsis. Despite of preoperative
antibiotic treatment, the sepsis rates have been reported to
vary from 0.25 to 1.5% in PNL studies, and in developing
country such as china, the incidence of urosepsis is rela-
tively higher and the status of urinary tract infection (UTI)
accompanied with nephrolithiasis should be characterized
with close concern [5, 6]. Since the early manifestation is
usually obscure, sepsis is often ignored in clinic. For many
urologists, the lack of standardizations in accurate diagnosis
of SIRS caused severe multiorgan dysfunction and even fetal
complications [7]. In fact, the criteria for the diagnosis of
infection and sepsis in nonnephrolithiasis patients should not
be applied to the cohort of nephrolithiasis patients because
the inflammatory mediators may alter during the process of
PNL, and traditional diagnostic criteria of SIRS and sepsis
lack diagnostic accuracy and are sometimes misleading.
Various markers have been studied for diagnosing sepsis.
At present, serum levels procalcitonin (PCT) and C-reactive
protein (CRP) are the two most common parameters in the
diagnosis of SIRS [8, 9]. However, the level of PCT increases
as a reflection of the severity of the body’s reaction to the
traumatic stimuli, so in the absence of signs of infection,
diagnostic performance of PCT for infection was low in the
cases like trauma and postoperation patients. It is not clear
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yet whether the increase of CRP in nephrolithiasis patients is
related to the presence of septic complications or is an effect
of surgical-related trauma itself. White blood cell (WBC), a
criterion for sepsis, is routinely performed in almost every
patient but it is influenced by many noninfectious factors
[10, 11]. So in patients with nephrolithiasis that received PNL,
there is a need for reevaluation of inflammation markers for
the diagnosis of SIRS.
Soluble cluster of differentiation 14 subtype (sCD14-
ST), also called presepsin, is cleaved from the monocyte/
macrophage-specific CD14 receptor complex after binding
with lipopolysaccharides (LPS) and LPS binding protein
(LPB) during systemic infections [12–15]. Aspartate pro-
teases, including cathepsin D, were one of the lysosomal
enzymes that are related to the production of presepsin [13]. It
is reported that measurement of presepsin concentrations is
useful for diagnosis of sepsis and also for monitoring clinical
responses to therapeutic interventions [16, 17].
Here, we intend to evaluate the diagnostic ability of pre-
sepsin in the differential diagnosis including SIRS, infection,
or sepsis and to compare its diagnostic value with other
markers, mainly as CRP, PCT, and WBC in patients of neph-
rolithiasis presenting with SIRS. Diagnosis of SIRS in the
nephrolithiasis patients is sometimes not timely; hence a
marker that is able to distinguish inflammatory response to
infection from other causes of inflammation should be tried
in clinical practice and the advantage of using presepsin as
a marker is its accuracy, which will be demonstrated in this
work [18]. Besides, we have analyzed the data from samples
collected during the immediate occurrence of SIRS and the
once more 24 h later.
2. Materials and Methods
2.1. Patients. Between July 2013 and June 2014, all in-patients
clinically diagnosed as nephrolithiasis by imaging examina-
tion at our department were enrolled in the study. Diagnostic
criteria of SIRS were based on clinical manifestations and
laboratory findings, according to (American College of Chest
Physicians/Society of Critical Care Medicine) ACCP/SCCM
guidelines: body temperature >38.5∘C or <36∘C, heart rate
(HR) > 90/min, respiratory rate (RR) > 20/min, or PaCO
2
<
32mmHg and leukocyte count >12 × 109/L or <4 × 109/L,
levels > 10% of immature neutrophils; then the simultaneous
presence of two or more of these criteria clinical/laboratory
signs was defined as SIRS [19]. In this study, there were 24
men and 15 women in the nephrolithiasis with SIRS group,
and 16 men and 9 women in the non-SIRS group. Blood
cultures were taken routinely and urine cultures are taken
when necessary. Culture (+) sepsis diagnosis could be made
the day culture results were taken but sepsis day was labeled
retrospectively as the day blood culture was sampled. At all
timing samples, whole criteria were evaluated and situation
was classified as SIRS and non-SIRS according to ACCP
criteria by the samemicrobiologist and urologists. To exclude
presepsin levels thatmight have increased due to acute kidney
injury (AKI), we have used the diagnostic criteria for AKI
which are proposed by the Acute Kidney Injury Network
(AKIN) [20]: an abrupt (within 48 h) reduction in kidney
function is currently defined as an absolute increase in serum
creatinine levels of more than or equal to 26.4 𝜇mol/L, a
percentage increase in serum creatinine ofmore than or equal
to 50%. We have also collected blood urea nitrogen (BUN),
serum creatinine (SCr), and urinary WBC at the time when
SIRS was evident and once more 48 h after therapy. Approval
for the study was received in advance from the local ethics
committee of our institution.
2.2. Samples Collection and Detection. After obtaining
informed consent, the serum samples of SIRS patients
were obtained immediately when the symptoms occurred
before antibiotics intervention. The second and third serum
samples were obtained after 6 h and 24 h. Plasma and serum
supernatants were obtained after centrifugation of the blood
samples for 10min, following which samples were stored
in 0.5mL aliquots at −80∘C in order to avoid multiple
freeze-thaw cycles. Plasma presepsin levels were measured
by a chemiluminescent enzyme immunoassay (Pathfast,
Mitsubishi Chemical Medicine Corporation, Japan) system.
PCT levels were performed on an E 170 autoanalyzer (Roche
Diagnostics, Tokyo, Japan) which was operated according
to the electrochemiluminescence immunoassay (ECLIA)
measurement principle [15]. CRP analysis was performed by a
nephelometricmethodwith BN II analyzer (Date Behring BN
II, Siemens Healthcare Diagnostic Inc., Marburg, Germany)
and WBC analysis was performed by Sysmex XT-2000i
(Sysmex Europe GMBH) and cultures were performed by
(BacT/Alert 3D; BioMerreux, Inc.) and were evaluated by the
same physician. The absorbance of samples was measured
at wavelength of 450 nm using a VERSA max tunable
microplate reader (Molecular Devices, California, USA).
2.3. Statistical Analysis. Data obtained by measurements
were given as mean ± one standard deviation. The main
data collected for assessing patient symptoms and laboratory
parameters, such as presepsin, serum PCT, CRP and WBC
were compared by the Mann-WhitneyU test. The concentra-
tions of presepsin in SIRS patients when untreated and 48 h
following treatment were compared by Student’s paired t-test.
Concentrations were expressed as median (5–95 percentile)
and AUC ROC values as percent (%).
The receiver-operating characteristic (ROC) curve anal-
yses were performed with calculation of area under the
curve (AUC) for diagnosis of sepsis, severe sepsis, and septic
shock during the first day of SIRS. The area under the curve
(AUC) was reported to evaluate the utility of these potential
markers in discriminating SIRS patients from the non-SIRS
simple nephrolithiasis group. An AUC of 0.5 is considered
to be no better than expected by chance, whereas a value of
1.0 signifies a perfect biomarker. Sensitivity, specificity, and
cutoff were calculated in accordance with ROC curves for
each biochemical marker. SPSS software (version 17.0, SPSS
Inc., Chicago, IL, USA) and MedCalc (Medical Calculation
Version 12.4.0, Belgium) were used for statistical analyses,
and 𝑃 < 0.05 was considered statistically significant.
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Table 1: General information of nephrolithiasis patients with SIRS and non-SIRS.
Characteristics SIRS group Non-SIRS group Total
Number of cases (𝑛) 39 25 64
Gender (M/F) 24/15 16/9 40/24
Mean age (years) (mean ± SD) 39.2 ± 9.7 34.9 ± 7.1# 36.7 ± 8.2
Stone size (length × width × height/mm) 20 ± 4 × 8 ± 2 × 10 ± 6 15 ± 6 × 9 ± 3 × 8 ± 2 /
Body temperature (∘C) 38.5 ± 0.6 36.8 ± 0.3∗ /
Blood WBC (×109/L) 12.9 ± 2.3 6 ± 1.2∗ /
Bacteria culture positive (𝑁/%) 8 (20.5%) 0∗ /
Blood urea nitrogen (mmol/L) (mean ± SD) 7.1 ± 1.7 5.4 ± 1.2∗ /
Serum creatinine (𝜇mol/L) (mean ± SD) 84.19 ± 7.55 67.63 ± 10.43∗ /
Urinary WBC (/hp) (mean ± SD) 30 ± 13 4 ± 3∗ /
Length of stay in hospital (days) (mean ± SD) 16.5 ± 7.1 9.4 ± 8.4∗ /
#
𝑃 > 0.05; SIRS group versus non-SIRS group.
∗
𝑃 < 0.05; SIRS group versus non-SIRS group.
Standard BUN 1.8–7.1mmol/L; standard SCr 59–104mmol/L.
Table 2: Laboratory markers by definitive diagnosis in SIRS and non-SIRS patients.
Laboratory findings Non-SIRS groupMedian (5–95%)
SIRS group (5–95%)
𝑃
Untreated 6 h reexamination 24 h reexamination
Presepsin (pg/mL) 178 (70–312) 452 (129–880) 584 (154–1331) 660 (190–1705) <0.001a,b,c,e, 0.009d, 0.26f
PCT (ng/mL) 0.172 (0.017–1.215) 0.973 (0.341–4.794) 1.425 (0.698–9.716) 1.864 (0.712–15.392) <0.001a,b,c,d,e, 0.005f
CRP (mg/L) 6.2 (1.8–9.7) 15.9 (4.9–36.5) 28.4 (7.1–64.2) 55.2 (13.2–82.5) <0.001a,b,c,d,e, 0.003f
aUntreated in SIRS group versus non-SIRS group; b6 h reexamination in SIRS group versus non-SIRS; c24 h reexamination in SIRS group versus non-SIRS
group; duntreated versus 6 h reexamination; euntreated versus 24 h reexamination; f6 h reexamination versus 24 h reexamination.
3. Results
This study included 39 nephrolithiasis patients with SIRS in
SIRS group and 25 simple nephrolithiasis patients in the non-
SIRS group.The demographic parameters are listed in Table 1.
There was no difference in the mean age between patients
in SIRS group or non-SIRS group (𝑃 > 0.05) (Table 1).
The analysis of the clinical data revealed stone size was
not statistically different between SIRS group and non-SIRS
group (𝑃 > 0.05), which suggested that the stone size was
not an impact factor between different groups in our study.
With reference to the SIRS criteria, the body temperature
and blood WBC value were expressively higher in patients
with SIRS as compared to those without SIRS (𝑃 < 0.05).
In addition, urinary WBC values in the untreated patients in
SIRS group were different as compared with non-SIRS group.
Body temperature and WBC data were described in Table 1.
The BUN and SCr levels in the SIRS group were significantly
higher than those of non-SIRS group (𝑃 < 0.05), and the
length of stay in hospital was also longer in the SIRS group
(16.5 ± 7.1 d in SIRS group versus 9.4 ± 8.4 d in the non-SIRS
group, 𝑃 < 0.05) (Table 1).
The presepsin concentrations were 178 (70–312) pg/mL in
the non-SIRS group; 452 (129–880) ng/mL in the untreated
SIRS group; 584 (154–1331) pg/mL in the SIRS group reex-
amination after 6 h and 660 (190–1705) pg/mL after 24 h
(Table 2). The levels of presepsin were significantly higher in
SIRS group compared to the non-SIRS group (𝑃 < 0.001).
Furthermore, the levels in the SIRS group were much higher
in the reexamination after 6 h and 24 h (𝑃 = 0.009, 𝑃 <
0.01) (Figure 1). When presepsin was compared according to
whether patients after receiving treatment or not, there was
no difference between the reexamination after 6 h and after
24 h (𝑃 = 0.26) (Figure 1).
The serum PCT concentrations were 0.172 (0.017–
1.215) ng/mL in the non-SIRS group and 0.973 (0.341–
4.794) in the untreated SIRS group; PCT was 1.425 (0.698–
9.176) ng/mL and 1.864 (0.712–15.392) ng/mL, respectively, in
the SIRS group that was redetermined 6 h and 24 h after
treatment. There were also statistically significant differences
found between the non-SIRS group and the SIRS group (𝑃 <
0.001). Additionally, in the SIRS group the level of PCT in
the reexamination was even higher than that found in the
group where PCTwas determined when SIRS happened (𝑃 <
0.001).
The serum CRP concentrations in the non-SIRS group,
in the untreated SIRS group, and redetermined 6 h and 24 h
after treatment were 6.2 (1.8–9.7), 15.9 (4.9–36.5), 28.4 (7.1–
64.2), and 55.2 (13.2–82.5)mg/L, respectively. There were
statistically significant differences found between the non-
SIRS group and the SIRS group (𝑃 < 0.001) (Table 2). Timely
detection results are shown in Figure 2.
To evaluate laboratory markers, we have used the ROC
curve method wherein the areas under the curve (AUCs)
for plasma presepsin, PCT, and CRP in the SIRS group were
84.6%, 79.6%, and 71.8%, respectively (Table 3). Therefore,
presepsin displayed a higher sensitivity and specificity (74.7%
and 88.4%) than PCT (72.6% and 85.3%) andCRP (70.7% and
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Table 3: Diagnostic performance of biomarkers in nephrolithiasis with SIRS patients.
Presepsin (pg/mL) PCT (ng/mL) CRP (mg/mL)
AUC (95% CI) 84.6 (79.8∼87.1) 79.6 (75.3–82.5) 71.8 (68.7∼73.9)
Cutoff 389 0.641 11.3
Sensitivity (95% CI) 74.7 (67.1–78.5) 72.6 (62.8–76.4) 70.7 (66.9–73.6)










































Figure 1: Comparison of serum levels of presepsin in different group
of patients. Data are compared by Mann-Whitney U test. Levels are
represented as ratio to the average of controls.
75.2%). The optimal cut-off points of these three markers in
the SIRS group are shown in Table 3. Daily monitorship data
are shown in Figure 3.
4. Discussion
SIRS is an important and predictive factor for UTI, especially
in urinary sepsis. However, traditional urinary tests could not
efficiently reflect the progression of SIRS that had originated
from the urinary tract. Mariappan et al. observed 54 patients
and found that 42% of patients had a positive upper urinary
tract culture (pelvic and stone), whereas only 5.6% had a
positive urine culture from the bladder [7]. According to
the study of Margel et al., positive detection of stone or
urine culture is accepted as a relative risk for SIRS. They
declared that bladder urine culture was insufficient to reveal
an infection of the upper urinary tract and also reported that
bigger stones are more likely to become infected than those
smaller in size [21]. Similarly in our study, bacterial culture
positive rates in the SIRS group were only 20.5%. In addition,
our study and that of others emphasize that in the clinic, the



















Figure 2: Comparison ROC curves of presepsin, PCT, and CRP in
the diagnosis of SIRS in nephrolithiasis patients.
Presepsin is a glycoprotein expressed on the membrane
surface of monocytes and macrophages and serves as a
receptor for lipopolysaccharides (LPSs) and LPS-binding
proteins (LPBs). By activating a proinflammatory signaling
cascade on contact with infectious agents, CD14 has a role
as a recognition molecule in the innate immune response
against microorganisms. During inflammation, plasma pro-
tease activity generates soluble CD14 (sCD14) fragments. One
of them, called sCD14 subtype (sCD14-ST), or presepsin, is
normally present in very low concentrations in the serum of
healthy individuals and has been shown to be increased in
response to bacterial infections [22]. Chenevier-Gobeaux et
al. found a significant difference in serum presepsin levels
between critically ill children with SIRS as compared with
thosewith septic shock, even in the absence ofAKI [23].Thus,
presepsin might represent a novel marker of SIRS, similar to
that provided by measuring the levels of CRP and PCT.
In our study, we evaluated presepsin and found that
presepsin was noticeably higher in the SIRS group as com-
pared to the non-SIRS group (178 (70–312) and 452 (129–
880) pg/mL, 𝑃 < 0.001). This might be due to the
accumulation of neutrophils within the tubular lumen during
systemic inflammation and sepsis, which could lead to a























Figure 3: Repeat detection of threemarkers for SIRS in nephrolithi-
asis patients. Concentration axis: presepsin (pg./mL); PCT (ng/mL);
CRP (mg/L).
noticeable increase of presepsin. Our study was concordant
with other studies done with children presenting with sepsis
[24]. Presepsin has been reported to be increased in AKI and
chronic kidney diseases (CKD), and in our study patients
presenting with CKD were excluded [25]. The mean levels
of serum BUN and SCr in the SIRS group were both in the
normal range, so we also excluded the involvement AKI. A
previous report disclosed that peak presepsin levels were seen
in the early stages of infection in animal models [26]. We
aimed to assess whether presepsin would be maintained at
a relatively higher level in the early stage of SIRS. We found
that 6 h after the occurrence of SIRS, the concentration of
presepsinwas higher than that determined during active SIRS
(584 (154–1331) and 452 (129–880) pg/mL, 𝑃 < 0.001), but
was not different with 24 h reexamination (660 (190–1705)
and 584 (154–1331) pg/mL, 𝑃 = 0.26). Thus, in the early stage
of SIRS before the occurrence of AKI, determination of the
levels of presepsin might be an objective parameter before
clinical diagnosis of AKI.
PCT and CRP have been used as classic markers in the
clinic for diagnosis and monitoring of SIRS during attempts
to cure critically ill patients. Mokart et al. suggested that PCT
could be a more reliable marker than CRP in septic patients
[27]. However, another study reported that there were some
limitations in using PCT as predicative marker in SIRS and
sepsis, since the levels might be low or indeterminate in the
early stage of the disease [28]. In our study, both PCT and
CRP were significantly higher in the SIRS group as compared
to the non-SIRS group. We have further evaluated the
diagnostic value of PCT and CRP compared with presepsin
using ROC curves analysis, whereas we found that AUCs
of three markers were not different statistically (𝑃 > 0.05).
Therefore, at the early onset of SIRS, the measurements of
presepsin, PCT, andCRPwere all highly sensitive and specific
markers of SIRS. It is noteworthy that this is an initial study
in the cohort of nephrolithiasis. However, WBC’s ineffective
diagnostic performance should be kept in mind.
In addition, we have valued the redetermined data 6 h
and 24 h after treatment. The increase of presepsin was lower
than PCT and CRP. Analysis revealed that in the early stage
of SIRS, the presepsin reached the peak fast compared to
PCT and CRP in the value of diagnosis. This observation
has further enhanced the diagnostic importance of presepsin.
In Shozushima et al.’s study, the usefulness of presepsin for
diagnosis of bacterial infections was comparable to PCT,
but the clinical specificity of presepsin was much higher
than PCT. Higher false positive rate of PCT resulted from a
subgroup of patients with secondary trauma, indicating that
presepsin levels were less influenced by traumatic situations
than the PCT levels [13].
In conclusion, we conclude that in our study, measure-
ment of presepsin was a highly sensitive predictor and a
useful monitoring marker in the early stage of SIRS for
patients with nephrolithiasis. The ability of biomarkers, such
as presepsin, to discern both the onset and resolution of
SIRS will further validate use of such biomarkers in clinical
diagnosis and greatly enhance our understanding of SIRS
in the nephrolithiasis cohort. Further validation of serum
presepsin as putative biomarkers of SIRS in this population
will require a multicenter randomized study.
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